With 3 years of adjuvant therapy in KIT+ GIST patients', at 5-year analysis, GLIVEC provided1
92% OVERALL SURVIVAL
66% RECURRENCE-FREE SURVIVAL
Download NEW 3 year adjuvant Clinical Results
Gastrointestinal Stromal Tumor (GIST) Risk of Recurrence Calculator
Download this convenient interactive tool to quickly assess your patients risk of KIT+GIST recurrence, based on tumor size, tumor site, and mitotic rate.